PCSK9 and metabolic syndrome: The possible mechanism of action of amla in regulating dyslipidemia is via PCSK9-inhibition, PPAR-α agonism (Variya et al., 2016; Variya et al., 2018), as well as its strong antioxidant effects (Antony et al., 2008a; Gul et al., 2022).